FDA Genomics Policy: Data Will Be Used In Reviews Only By Sponsor Consent
Executive Summary
FDA will leave the decision to use a therapeutic product's pharmacogenomic data in regulatory submissions to the sponsor and an FDA review group
You may also be interested in...
Biomarkers, Communications Are Key To Accelerating R&D, FDA Says
Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12
Biomarkers, Communications Are Key To Accelerating R&D, FDA Says
Genentech's Herceptin is a good example of how the tradeoffs in targeted drug development can work out medically and commercially, FDA Commissioner McClellan told an IBC meeting in Boston Aug. 12
Pharmacogenomic Data “Regulatory Impact” To Be Outlined In Guidance
The regulatory impact of different categories of pharmacogenomic data will be addressed in a draft guidance, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said at FDA's Science Board Advisory Committee meeting April 9